{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["PI3K/Akt/mTOR pathway", "natural compounds", "prostate cancer", "small-molecule mTOR inhibitors"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34452154", "DateRevised": {"Year": "2021", "Month": "08", "Day": "31"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "08", "Day": "03"}], "Language": ["eng"], "ELocationID": ["1195", "10.3390/pharmaceutics13081195"], "Journal": {"ISSN": "1999-4923", "JournalIssue": {"Volume": "13", "Issue": "8", "PubDate": {"Year": "2021", "Month": "Aug", "Day": "03"}}, "Title": "Pharmaceutics", "ISOAbbreviation": "Pharmaceutics"}, "ArticleTitle": "Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention.", "Abstract": {"AbstractText": ["The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the malignant transformation, growth, proliferation, and metastasis of various cancers and solid tumors. Relevant connections between the PI3K/Akt/mTOR pathway, cell survival, and prostate cancer (PC) provide a great therapeutic target for PC prevention or treatment. Recent studies have focused on small-molecule mTOR inhibitors or their usage in coordination with other therapeutics for PC treatment that are currently undergoing clinical testing. In this study, the function of the PI3K/Akt/mTOR pathway, the consequence of its dysregulation, and the development of mTOR inhibitors, either as an individual substance or in combination with other agents, and their clinical implications are discussed. The rationale for targeting the PI3K/Akt/mTOR pathway, and specifically the application and potential utility of natural agents involved in PC treatment is described. In addition to the small-molecule mTOR inhibitors, there are evidence that several natural agents are able to target the PI3K/Akt/mTOR pathway in prostatic neoplasms. These natural mTOR inhibitors can interfere with the PI3K/Akt/mTOR pathway through multiple mechanisms; however, inhibition of Akt and suppression of mTOR 1 activity are two major therapeutic approaches. Combination therapy improves the efficacy of these inhibitors to either suppress the PC progression or circumvent the resistance by cancer cells."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran 1941933111, Iran."}], "LastName": "Roudsari", "ForeName": "Nazanin Momeni", "Initials": "NM"}, {"Identifier": ["0000-0003-0502-6114"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran 1941933111, Iran."}], "LastName": "Lashgari", "ForeName": "Naser-Aldin", "Initials": "NA"}, {"Identifier": ["0000-0003-3957-3300"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Institute of Medicinal Plants, Academic Center for Education, Culture and Research, Tehran 1417614411, Iran."}, {"Identifier": [], "Affiliation": "Toxicology and Disease Group, Pharmaceutical Sciences Research Center, Institute of Pharmaceutical Sciences, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran."}, {"Identifier": [], "Affiliation": "Gastrointestinal Pharmacology Interest Group, Universal Scientific Education and Research Network, Tehran 1417614411, Iran."}], "LastName": "Momtaz", "ForeName": "Saeideh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran 1941933111, Iran."}], "LastName": "Abaft", "ForeName": "Shaghayegh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran 1941933111, Iran."}], "LastName": "Jamali", "ForeName": "Fatemeh", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran 1941933111, Iran."}], "LastName": "Safaiepour", "ForeName": "Pardis", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran 1941933111, Iran."}], "LastName": "Narimisa", "ForeName": "Kiyana", "Initials": "K"}, {"Identifier": ["0000-0003-4528-6084"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Lake Erie Collage of Osteopathic Medicine, Bradenton, FL 34211, USA."}], "LastName": "Jackson", "ForeName": "Gloria", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pine View School, Osprey, FL 34229, USA."}], "LastName": "Bishayee", "ForeName": "Anusha", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran 1417614411, Iran."}, {"Identifier": [], "Affiliation": "Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 1417614411, Iran."}], "LastName": "Rezaei", "ForeName": "Nima", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran 1941933111, Iran."}, {"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Institute of Medicinal Plants, Academic Center for Education, Culture and Research, Tehran 1417614411, Iran."}, {"Identifier": [], "Affiliation": "Toxicology and Disease Group, Pharmaceutical Sciences Research Center, Institute of Pharmaceutical Sciences, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran."}, {"Identifier": [], "Affiliation": "Gastrointestinal Pharmacology Interest Group, Universal Scientific Education and Research Network, Tehran 1417614411, Iran."}], "LastName": "Abdolghaffari", "ForeName": "Amir Hossein", "Initials": "AH"}, {"Identifier": ["0000-0001-9159-960X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Lake Erie Collage of Osteopathic Medicine, Bradenton, FL 34211, USA."}], "LastName": "Bishayee", "ForeName": "Anupam", "Initials": "A"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pharmaceutics", "NlmUniqueID": "101534003", "ISSNLinking": "1999-4923"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Rawla P. Epidemiology of Prostate Cancer. World J. Oncol. 2019;10:63\u201389. doi: 10.14740/wjon1191.", "ArticleIdList": ["10.14740/wjon1191", "PMC6497009", "31068988"]}, {"Citation": "Sartor O., de Bono J.S. Metastatic prostate cancer. N. Engl. J. Med. 2018;378:645\u2013657. doi: 10.1056/NEJMra1701695.", "ArticleIdList": ["10.1056/NEJMra1701695", "29412780"]}, {"Citation": "Wang G., Zhao D., Spring D.J., DePinho R.A. Genetics and biology of prostate cancer. Genes Dev. 2018;32:1105\u20131140. doi: 10.1101/gad.315739.118.", "ArticleIdList": ["10.1101/gad.315739.118", "PMC6120714", "30181359"]}, {"Citation": "Mohler J.L., Kantoff P.W., Armstrong A.J., Bahnson R.R., Cohen M., D\u2019Amico A.V., Eastham J.A., Enke C.A., Farrington T.A., Higano C.S., et al. Prostate Cancer, Version 2.2014. J. Natl. Compr. Cancer Netw. 2014;12:686\u2013718. doi: 10.6004/jnccn.2014.0072.", "ArticleIdList": ["10.6004/jnccn.2014.0072", "24812137"]}, {"Citation": "Serrano N.A., Anscher M.S. Favorable vs unfavorable intermediate-risk prostate cancer: A review of the new classification system and its impact on treatment recommendations. Oncology. 2016;30:229\u2013236.", "ArticleIdList": ["26984216"]}, {"Citation": "Litwin M.S., Tan H.-J. The diagnosis and treatment of prostate cancer: A review. JAMA. 2017;317:2532\u20132542. doi: 10.1001/jama.2017.7248.", "ArticleIdList": ["10.1001/jama.2017.7248", "28655021"]}, {"Citation": "Tan M.H.E., Li J., Xu H.E., Melcher K., Yong E.-L. Androgen receptor: Structure, role in prostate cancer and drug discovery. Acta. Pharm. Sin. 2015;36:3\u201323. doi: 10.1038/aps.2014.18.", "ArticleIdList": ["10.1038/aps.2014.18", "PMC4571323", "24909511"]}, {"Citation": "Sarkar F.H., Li Y., Wang Z., Kong D. Novel targets for prostate cancer chemoprevention. Endocr. Relat. Cancer. 2010;17:R195\u2013R212. doi: 10.1677/ERC-10-0074.", "ArticleIdList": ["10.1677/ERC-10-0074", "PMC2976036", "20576802"]}, {"Citation": "Lien E.C., Lyssiotis C.A., Cantley L.C. Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer. In: Cramer T., A. Schmitt C., editors. Metabolism in Cancer. Springer International Publishing; Basel, Switzerland: 2016. pp. 39\u201372.", "ArticleIdList": ["27557534"]}, {"Citation": "Yang J., Nie J., Ma X., Wei Y., Peng Y., Wei X. Targeting PI3K in cancer: Mechanisms and advances in clinical trials. Mol. Cancer. 2019;18:1\u201328. doi: 10.1186/s12943-019-0954-x.", "ArticleIdList": ["10.1186/s12943-019-0954-x", "PMC6379961", "30782187"]}, {"Citation": "Morgan T.M., Koreckij T.D., Corey E. Targeted therapy for advanced prostate cancer: Inhibition of the PI3K/Akt/mTOR pathway. Curr. Cancer Drug Targets. 2009;9:237\u2013249. doi: 10.2174/156800909787580999.", "ArticleIdList": ["10.2174/156800909787580999", "PMC2921605", "19275762"]}, {"Citation": "Nitulescu G.M., Margina D., Juzenas P., Peng Q., Olaru O.T., Saloustros E., Fenga C., Spandidos D.A., Libra M., Tsatsakis A.M. Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use. Int. J. Oncol. 2016;48:869\u2013885. doi: 10.3892/ijo.2015.3306.", "ArticleIdList": ["10.3892/ijo.2015.3306", "PMC4750533", "26698230"]}, {"Citation": "Chang L., Graham P.H., Ni J., Hao J., Bucci J., Cozzi P.J., Li Y. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Crit. Rev. Oncol. Hematol. 2015;96:507\u2013517. doi: 10.1016/j.critrevonc.2015.07.005.", "ArticleIdList": ["10.1016/j.critrevonc.2015.07.005", "26253360"]}, {"Citation": "Hua H., Kong Q., Zhang H., Wang J., Luo T., Jiang Y. Targeting mTOR for cancer therapy. J. Hematol. Oncol. 2019;12:71. doi: 10.1186/s13045-019-0754-1.", "ArticleIdList": ["10.1186/s13045-019-0754-1", "PMC6612215", "31277692"]}, {"Citation": "Herbert T.P., Tee A.R., Proud C.G. The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J. Biol. Chem. 2002;277:11591\u201311596. doi: 10.1074/jbc.M110367200.", "ArticleIdList": ["10.1074/jbc.M110367200", "11799119"]}, {"Citation": ". A long and winding sTORy. Nat. Cell Biol. 2017;19:1131. doi: 10.1038/ncb3624.", "ArticleIdList": ["10.1038/ncb3624", "28960201"]}, {"Citation": "Cinar B., De Benedetti A., Freeman M.R. Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res. 2005;65:2547\u20132553. doi: 10.1158/0008-5472.CAN-04-3411.", "ArticleIdList": ["10.1158/0008-5472.CAN-04-3411", "15805247"]}, {"Citation": "Dancey J. mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol. 2010;7:209. doi: 10.1038/nrclinonc.2010.21.", "ArticleIdList": ["10.1038/nrclinonc.2010.21", "20234352"]}, {"Citation": "Center M.M., Jemal A., Lortet-Tieulent J., Ward E., Ferlay J., Brawley O., Bray F. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 2012;61:1079\u20131092. doi: 10.1016/j.eururo.2012.02.054.", "ArticleIdList": ["10.1016/j.eururo.2012.02.054", "22424666"]}, {"Citation": "Kimura T., Egawa S. Epidemiology of prostate cancer in Asian countries. Int. J. Urol. 2018;25:524\u2013531. doi: 10.1111/iju.13593.", "ArticleIdList": ["10.1111/iju.13593", "29740894"]}, {"Citation": "Pourmand G., Salem S., Mehrsai A., Lotfi M., Amirzargar M.A., Mazdak H., Roshani A., Kheirollahi A., Kalantar E., Baradaran N. The risk factors of prostate cancer: A multicentric case-control study in Iran. Asian Pac. J. Cancer Prev. 2007;8:422\u2013428.", "ArticleIdList": ["18159981"]}, {"Citation": "Suzuki T., Matsuo K., Wakai K., Hiraki A., Hirose K., Sato S., Ueda R., Tajima K. Effect of familial history and smoking on common cancer risks in Japan. Cancer Interdiscip. Int. J. Am. Cancer Soc. 2007;109:2116\u20132123. doi: 10.1002/cncr.22685.", "ArticleIdList": ["10.1002/cncr.22685", "17410537"]}, {"Citation": "Masko E.M., Allott E.H., Freedland S.J. The relationship between nutrition and prostate cancer: Is more always better? Eur. Urol. 2013;63:810\u2013820. doi: 10.1016/j.eururo.2012.11.012.", "ArticleIdList": ["10.1016/j.eururo.2012.11.012", "PMC3597758", "23219353"]}, {"Citation": "Li H.X., Gao J.M., Liang J.Q., Xi J.M., Fu M., Wu Y.J. Vitamin D3 potentiates the growth inhibitory effects of metformin in DU 145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway. Clin. Exp. Pharmacol. Physiol. 2015;42:711\u2013717. doi: 10.1111/1440-1681.12409.", "ArticleIdList": ["10.1111/1440-1681.12409", "25903858"]}, {"Citation": "Matsuo H., Baba Y., Nair R.G., Arimura A., Schally A.V. Structure of the porcine LH-and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem. Biophys. Res. Commun. 1971;43:1334\u20131339. doi: 10.1016/S0006-291X(71)80019-0.", "ArticleIdList": ["10.1016/S0006-291X(71)80019-0", "4936338"]}, {"Citation": "Antonarakis E.S., Eisenberger M.A. Expanding treatment options for metastatic prostate cancer. N. Engl. J. Med. 2011;364:2055. doi: 10.1056/NEJMe1102758.", "ArticleIdList": ["10.1056/NEJMe1102758", "PMC3458507", "21612475"]}, {"Citation": "Sebesta E.M., Anderson C.B. The Surgical Management of Prostate Cancer. Semin. Oncol. 2017;44:347\u2013357. doi: 10.1053/j.seminoncol.2018.01.003.", "ArticleIdList": ["10.1053/j.seminoncol.2018.01.003", "29580436"]}, {"Citation": "Fitzpatrick J.M., de Wit R. Taxane mechanisms of action: Potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur. Urol. 2014;65:1198\u20131204. doi: 10.1016/j.eururo.2013.07.022.", "ArticleIdList": ["10.1016/j.eururo.2013.07.022", "23910941"]}, {"Citation": "Fizazi K., Smith M.R., Tombal B. Clinical development of darolutamide: A novel androgen receptor antagonist for the treatment of prostate cancer. Clin. Genitourin. Cancer. 2018;16:332\u2013340. doi: 10.1016/j.clgc.2018.07.017.", "ArticleIdList": ["10.1016/j.clgc.2018.07.017", "30197098"]}, {"Citation": "Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., Wongvipat J., Smith-Jones P.M., Yoo D., Kwon A. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787\u2013790. doi: 10.1126/science.1168175.", "ArticleIdList": ["10.1126/science.1168175", "PMC2981508", "19359544"]}, {"Citation": "Harris M.G., Coleman S.G., Faulds D., Chrisp P. Nilutamide. Drugs Aging. 1993;3:9\u201325. doi: 10.2165/00002512-199303010-00002.", "ArticleIdList": ["10.2165/00002512-199303010-00002", "8453188"]}, {"Citation": "Crawford E.D., Moul J.W., Sartor O., Shore N.D. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: Achieving testosterone levels below 20 ng/dl. Expert Opin. Drug Metab. Toxicol. 2015;11:1465\u20131474. doi: 10.1517/17425255.2015.1073711.", "ArticleIdList": ["10.1517/17425255.2015.1073711", "26293510"]}, {"Citation": "Kittai A.S., Blank J., Graff J.N. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer. Prostate. 2018;32:599\u2013602.", "ArticleIdList": ["30632129"]}, {"Citation": "De Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., Chi K.N., Jones R.J., Goodman O.B., Jr., Saad F. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 2011;364:1995\u20132005. doi: 10.1056/NEJMoa1014618.", "ArticleIdList": ["10.1056/NEJMoa1014618", "PMC3471149", "21612468"]}, {"Citation": "Parker C., Nilsson S., Heinrich D., Helle S.I., O\u2019sullivan J., Foss\u00e5 S.D., Chodacki A., Wiechno P., Logue J., Seke M. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 2013;369:213\u2013223. doi: 10.1056/NEJMoa1213755.", "ArticleIdList": ["10.1056/NEJMoa1213755", "23863050"]}, {"Citation": "Bilusic M., Madan R.A., Gulley J.L. Immunotherapy of prostate cancer: Facts and hopes. Clin. Cancer Res. 2017;23:6764\u20136770. doi: 10.1158/1078-0432.CCR-17-0019.", "ArticleIdList": ["10.1158/1078-0432.CCR-17-0019", "PMC5690854", "28663235"]}, {"Citation": "Mirkheshti N., Park S., Jiang S., Cropper J., Werner S.L., Song C.S., Chatterjee B. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer. Oncotarget. 2016;7:62240. doi: 10.18632/oncotarget.11404.", "ArticleIdList": ["10.18632/oncotarget.11404", "PMC5308723", "27557496"]}, {"Citation": "Gao Y., Gartenhaus R.B., Lapidus R.G., Hussain A., Zhang Y., Wang X., Dan H.C. Differential IKK/NF-\u03baB activity is mediated by TSC2 through mTORC1 in PTEN-null prostate cancer and tuberous sclerosis complex tumor cells. Mol. Cancer Res. 2015;13:1602\u20131614. doi: 10.1158/1541-7786.MCR-15-0213.", "ArticleIdList": ["10.1158/1541-7786.MCR-15-0213", "PMC4690470", "26374334"]}, {"Citation": "Wang L., Xiong H., Wu F., Zhang Y., Wang J., Zhao L., Guo X., Chang L.-J., Zhang Y., You M.J. Hexokinase 2-mediated Warburg effect is required for PTEN-and p53-deficiency-driven prostate cancer growth. Cell Rep. 2014;8:1461\u20131474. doi: 10.1016/j.celrep.2014.07.053.", "ArticleIdList": ["10.1016/j.celrep.2014.07.053", "PMC4360961", "25176644"]}, {"Citation": "Wright S.C.E., Vasilevski N., Serra V., Rodon J., Eichhorn P.J.A. Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Cancers. 2021;13:1538. doi: 10.3390/cancers13071538.", "ArticleIdList": ["10.3390/cancers13071538", "PMC8037590", "33810522"]}, {"Citation": "Nitulescu G.M., Van De Venter M., Nitulescu G., Ungurianu A., Juzenas P., Peng Q., Olaru O.T., Gr\u0103dinaru D., Tsatsakis A., Tsoukalas D. The Akt pathway in oncology therapy and beyond. Int. J. Oncol. 2018;53:2319\u20132331. doi: 10.3892/ijo.2018.4597.", "ArticleIdList": ["10.3892/ijo.2018.4597", "PMC6203150", "30334567"]}, {"Citation": "Rhodes N., Heerding D.A., Duckett D.R., Eberwein D.J., Knick V.B., Lansing T.J., McConnell R.T., Gilmer T.M., Zhang S.-Y., Robell K. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 2008;68:2366\u20132374. doi: 10.1158/0008-5472.CAN-07-5783.", "ArticleIdList": ["10.1158/0008-5472.CAN-07-5783", "18381444"]}, {"Citation": "Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004;10:594\u2013601. doi: 10.1038/nm1052.", "ArticleIdList": ["10.1038/nm1052", "15156201"]}, {"Citation": "Morgan T.M., Pitts T.E., Gross T.S., Poliachik S.L., Vessella R.L., Corey E. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate. 2008;68:861\u2013871. doi: 10.1002/pros.20752.", "ArticleIdList": ["10.1002/pros.20752", "PMC3162313", "18361409"]}, {"Citation": "Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug. Discov. 2009;8:627\u2013644. doi: 10.1038/nrd2926.", "ArticleIdList": ["10.1038/nrd2926", "PMC3142564", "19644473"]}, {"Citation": "Morad S.A., Schmid M., B\u00fcchele B., Siehl H.-U., El Gafaary M., Lunov O., Syrovets T., Simmet T. A novel semisynthetic inhibitor of the FRB domain of mammalian target of rapamycin blocks proliferation and triggers apoptosis in chemoresistant prostate cancer cells. Mol. Pharmacol. 2013;83:531\u2013541. doi: 10.1124/mol.112.081349.", "ArticleIdList": ["10.1124/mol.112.081349", "23208958"]}, {"Citation": "Silva V.R., Belozo F.L., Micheletti T.O., Conrado M., Stout J.R., Pimentel G.D., Gonzalez A.M. \u03b2-Hydroxy-\u03b2-methylbutyrate free acid supplementation may improve recovery and muscle adaptations after resistance training: A systematic review. Nutr. Res. 2017;45:1\u20139. doi: 10.1016/j.nutres.2017.07.008.", "ArticleIdList": ["10.1016/j.nutres.2017.07.008", "29037326"]}, {"Citation": "Travis R.C., Appleby P.N., Martin R.M., Holly J.M., Albanes D., Black A., Bueno-de-Mesquita H.B., Chan J.M., Chen C., Chirlaque M.-D. A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res. 2016;76:2288\u20132300. doi: 10.1158/0008-5472.CAN-15-1551.", "ArticleIdList": ["10.1158/0008-5472.CAN-15-1551", "PMC4873385", "26921328"]}, {"Citation": "Kimball S.R., Gordon B.S., Moyer J.E., Dennis M.D., Jefferson L.S. Leucine induced dephosphorylation of Sestrin2 promotes mTORC1 activation. Cell. Signal. 2016;28:896\u2013906. doi: 10.1016/j.cellsig.2016.03.008.", "ArticleIdList": ["10.1016/j.cellsig.2016.03.008", "PMC4899281", "27010498"]}, {"Citation": "Guo C., Liu S., Greenaway F., Sun M.-Z. Potential role of annexin A7 in cancers. Clin. Chim. Acta. 2013;423:83\u201389. doi: 10.1016/j.cca.2013.04.018.", "ArticleIdList": ["10.1016/j.cca.2013.04.018", "23639634"]}, {"Citation": "Liu S., Ge D., Chen L., Zhao J., Su L., Zhang S., Miao J., Zhao B. A small molecule induces integrin \u03b24 nuclear translocation and apoptosis selectively in cancer cells with high expression of integrin \u03b24. Oncotarget. 2016;7:16282. doi: 10.18632/oncotarget.7646.", "ArticleIdList": ["10.18632/oncotarget.7646", "PMC4941314", "26918348"]}, {"Citation": "Liu S., Li X., Lin Z., Su L., Yan S., Zhao B., Miao J. SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis. Cancer Lett. 2018;416:11\u201323. doi: 10.1016/j.canlet.2017.12.008.", "ArticleIdList": ["10.1016/j.canlet.2017.12.008", "PMC5777349", "29247827"]}, {"Citation": "Loberg R.D., Day L.L., Harwood J., Ying C., John L.N.S., Giles R., Neeley C.K., Pienta K.J. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia. 2006;8:578\u2013586. doi: 10.1593/neo.06280.", "ArticleIdList": ["10.1593/neo.06280", "PMC1601934", "16867220"]}, {"Citation": "Roca H., Varsos Z., Pienta K.J. CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J. Biol. Chem. 2008;283:25057\u201325073. doi: 10.1074/jbc.M801073200.", "ArticleIdList": ["10.1074/jbc.M801073200", "PMC2529129", "18611860"]}, {"Citation": "Roca H., Varsos Z.S., Pienta K.J. CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. Neoplasia. 2009;11:1309\u20131317. doi: 10.1593/neo.09936.", "ArticleIdList": ["10.1593/neo.09936", "PMC2794512", "20019839"]}, {"Citation": "McCarty M.F. Plant-based diets relatively low in bioavailable phosphate and calcium may aid prevention and control of prostate cancer by lessening production of fibroblast growth factor 23. Med. Hypotheses. 2017;99:68\u201372. doi: 10.1016/j.mehy.2017.01.001.", "ArticleIdList": ["10.1016/j.mehy.2017.01.001", "28110703"]}, {"Citation": "Kim H.J., Kim K.-H., Lee J., Oh J.J., Cheong H.S., Wong E.L., Yang B.-S., Byun S.S., Myung S.C. Single nucleotide polymorphisms in fibroblast growth factor 23 gene, FGF23, are associated with prostate cancer risk. BJU Int. 2014;114:303\u2013310. doi: 10.1111/bju.12396.", "ArticleIdList": ["10.1111/bju.12396", "24053368"]}, {"Citation": "David V., Martin A., Isakova T., Spaulding C., Qi L., Ramirez V., Zumbrennen-Bullough K.B., Sun C.C., Lin H.Y., Babitt J.L. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89:135\u2013146. doi: 10.1038/ki.2015.290.", "ArticleIdList": ["10.1038/ki.2015.290", "PMC4854810", "26535997"]}, {"Citation": "Yan G., Ru Y., Wu K., Yan F., Wang Q., Wang J., Pan T., Zhang M., Han H., Li X. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling. Prostate. 2018;78:166\u2013177. doi: 10.1002/pros.23461.", "ArticleIdList": ["10.1002/pros.23461", "29181846"]}, {"Citation": "Hasskarl J.  Small Molecules in Oncology. Springer Nature; Basingstoke, UK: 2018.  [(accessed on 1 August 2021)]. Everolimus; pp. 101\u2013123. Available online:  https://link.springer.com/chapter/10.1007%2F978-3-319-91442-8_8."}, {"Citation": "Alshaker H., Wang Q., B\u00f6hler T., Mills R., Winkler M., Arafat T., Kawano Y., Pchejetski D. Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1. Sci. Rep. 2017;7:3493. doi: 10.1038/s41598-017-03728-3.", "ArticleIdList": ["10.1038/s41598-017-03728-3", "PMC5471177", "28615679"]}, {"Citation": "Chen X., Cheng H., Pan T., Liu Y., Su Y., Ren C., Huang D., Zha X., Liang C. mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer. Mol. Carcinog. 2015;54:1086\u20131095. doi: 10.1002/mc.22177.", "ArticleIdList": ["10.1002/mc.22177", "25043657"]}, {"Citation": "Marques N., Sese M., C\u00e1novas V., Valente F., Bermudo R., De Torres I., Fern\u00e1ndez Y., Abasolo I., Fernandez P.L., Contreras H., et al. Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1. Oncogene. 2014;33:1124. doi: 10.1038/onc.2013.51.", "ArticleIdList": ["10.1038/onc.2013.51", "23455324"]}, {"Citation": "Thoreen C.C., Chantranupong L., Keys H.R., Wang T., Gray N.S., Sabatini D.M. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature. 2012;485:109. doi: 10.1038/nature11083.", "ArticleIdList": ["10.1038/nature11083", "PMC3347774", "22552098"]}, {"Citation": "Facompre N.D., Sinha I., El-Bayoumy K., Pinto J.T., Sinha R. Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells. Int. J. Cancer. 2012;131:2134\u20132142. doi: 10.1002/ijc.27468.", "ArticleIdList": ["10.1002/ijc.27468", "PMC3398165", "22307455"]}, {"Citation": "Thomas J.D., Dias L.M., Johannes G.J. Translational repression during chronic hypoxia is dependent on glucose levels. Rna. 2008;14:771\u2013781. doi: 10.1261/rna.857308.", "ArticleIdList": ["10.1261/rna.857308", "PMC2271361", "18268023"]}, {"Citation": "Dan H.C., Cooper M.J., Cogswell P.C., Duncan J.A., Ting J.P.-Y., Baldwin A.S. Akt-dependent regulation of NF-\u03baB is controlled by mTOR and Raptor in association with IKK. Genes Dev. 2008;22:1490\u20131500. doi: 10.1101/gad.1662308.", "ArticleIdList": ["10.1101/gad.1662308", "PMC2418585", "18519641"]}, {"Citation": "Squillace R.M., Miller D., Wardwell S.D., Wang F., Clackson T., Rivera V.M. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int. J. Oncol. 2012;41:425\u2013432. doi: 10.3892/ijo.2012.1487.", "ArticleIdList": ["10.3892/ijo.2012.1487", "PMC3582879", "22614157"]}, {"Citation": "Befani C.D., Vlachostergios P.J., Hatzidaki E., Patrikidou A., Bonanou S., Simos G., Papandreou C.N., Liakos P. Bortezomib represses HIF-1\u03b1 protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J. Mol. Med. 2012;90:45\u201354. doi: 10.1007/s00109-011-0805-8.", "ArticleIdList": ["10.1007/s00109-011-0805-8", "21909688"]}, {"Citation": "Zabala-Letona A., Arruabarrena-Aristorena A., Mart\u00edn-Mart\u00edn N., Fernandez-Ruiz S., Sutherland J.D., Clasquin M., Tomas-Cortazar J., Jimenez J., Torres I., Quang P. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. 2017;547:109. doi: 10.1038/nature22964.", "ArticleIdList": ["10.1038/nature22964", "PMC5505479", "28658205"]}, {"Citation": "Sachan R., Kundu A., Jeon Y., Choi W.S., Yoon K., Kim I.S., Kwak J.H., Kim H.S. Afrocyclamin A, a triterpene saponin, induces apoptosis and autophagic cell death via the PI3K/Akt/mTOR pathway in human prostate cancer cells. Phytomedicine. 2018;51:139\u2013150. doi: 10.1016/j.phymed.2018.10.012.", "ArticleIdList": ["10.1016/j.phymed.2018.10.012", "30466611"]}, {"Citation": "Boehmer A., Anastasiadis A.G., Feyerabend S., Nagele U., Kuczyk M., Schilling D., Corvin S., Merseburger A.S., Stenzl A. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: A single-center experience. Anticancer. Res. 2005;25:4481\u20134486.", "ArticleIdList": ["16334130"]}, {"Citation": "Zhang Y., Lapidus R.G., Liu P., Choi E.Y., Adediran S., Hussain A., Wang X., Liu X., Dan H.C. Targeting I\u03baB Kinase \u03b2/NF-\u03baB Signaling in Human Prostate Cancer by a Novel I\u03baB Kinase \u03b2 Inhibitor Cmpd A. Mol. Cancer Ther. 2016;15:1504\u20131514. doi: 10.1158/1535-7163.MCT-15-0999.", "ArticleIdList": ["10.1158/1535-7163.MCT-15-0999", "PMC4936938", "27196761"]}, {"Citation": "Wang Y., Mikhailova M., Bose S., Pan C.-X., White R.d., Ghosh P.M. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene. 2008;27:7106. doi: 10.1038/onc.2008.318.", "ArticleIdList": ["10.1038/onc.2008.318", "PMC2694040", "18776922"]}, {"Citation": "Abou-Kheir W.G., Hynes P.G., Martin P.L., Pierce R., Kelly K. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model. Stem Cells. 2010;28:2129\u20132140. doi: 10.1002/stem.538.", "ArticleIdList": ["10.1002/stem.538", "PMC7454246", "20936707"]}, {"Citation": "Misra U.K., Pizzo S.V. Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: Assembly of a multiprotein signaling complex. J. Cell. Biochem. 2012;113:1488\u20131500. doi: 10.1002/jcb.24018.", "ArticleIdList": ["10.1002/jcb.24018", "22173835"]}, {"Citation": "Leu W.-J., Swain S.P., Chan S.-H., Hsu J.-L., Liu S.-P., Chan M.-L., Yu C.-C., Hsu L.-C., Chou Y.-L., Chang W.-L. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: The role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways. Oncotarget. 2016;7:76995. doi: 10.18632/oncotarget.12765.", "ArticleIdList": ["10.18632/oncotarget.12765", "PMC5363565", "27769069"]}, {"Citation": "Lian X., Gu J., Gao B., Li Y., Damodaran C., Wei W., Fu Y., Cai L. Fenofibrate inhibits mTOR-p70S6K signaling and simultaneously induces cell death in human prostate cancer cells. Biochem. Biophys. Res. Commun. 2018;496:70\u201375. doi: 10.1016/j.bbrc.2017.12.168.", "ArticleIdList": ["10.1016/j.bbrc.2017.12.168", "29305864"]}, {"Citation": "Yan Y., Du C., Li G., Chen L., Yan Y., Chen G., Hu W., Chang L. CO suppresses prostate cancer cell growth by directly targeting LKB1/AMPK/mTOR pathway in vitro and in vivo. Urol. Oncol. 2018;36:312e1\u2013312e8. doi: 10.1016/j.urolonc.2018.02.013.", "ArticleIdList": ["10.1016/j.urolonc.2018.02.013", "29566977"]}, {"Citation": "Du Y.-F., Long Q.-Z., Shi Y., Liu X.-G., Li X.-D., Zeng J., Gong Y.-G., Wang X.-Y., He D.-L. Downregulation of mTOR by lentivirus inhibits prostate cancer cell growth. Int. J. Clin. Exp. Pathol. 2014;7:923.", "ArticleIdList": ["PMC3971294", "24695460"]}, {"Citation": "Ellis L., Ku S., Ramakrishnan S., Lasorsa E., Azabdaftari G., Godoy A., Pili R. Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer. Oncotarget. 2013;4:2225. doi: 10.18632/oncotarget.1314.", "ArticleIdList": ["10.18632/oncotarget.1314", "PMC3926822", "24163230"]}, {"Citation": "Hart S., Novotny-Diermayr V., Goh K.C., Williams M., Tan Y.C., Ong L.C., Cheong A., Ng B.K., Amalini C., Madan B. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol. Cancer Ther. 2013;12:151\u2013161. doi: 10.1158/1535-7163.MCT-12-0466.", "ArticleIdList": ["10.1158/1535-7163.MCT-12-0466", "PMC3588144", "23270925"]}, {"Citation": "Chang W.-L., Hsu L.-C., Leu W.-J., Chen C.-S., Guh J.-H. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: A crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation. Oncotarget. 2015;6:39806. doi: 10.18632/oncotarget.5655.", "ArticleIdList": ["10.18632/oncotarget.5655", "PMC4741862", "26447757"]}, {"Citation": "Yu P., Ye L., Wang H., Du G., Zhang J., Zhang J., Tian J. NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways. Tumor Biol. 2015;36:2143\u20132153. doi: 10.1007/s13277-014-2824-x.", "ArticleIdList": ["10.1007/s13277-014-2824-x", "25398692"]}, {"Citation": "Gravina G.L., Mancini A., Scarsella L., Colapietro A., Jitariuc A., Vitale F., Marampon F., Ricevuto E., Festuccia C. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models. Tumor Biol. 2016;37:341\u2013351. doi: 10.1007/s13277-015-3725-3.", "ArticleIdList": ["10.1007/s13277-015-3725-3", "26219891"]}, {"Citation": "Kim A., Im M., Ma J.Y. Ethanol extract of Remotiflori radix induces endoplasmic reticulum stress-mediated cell death through AMPK/mTOR signaling in human prostate cancer cells. Sci. Rep. 2015;5:8394. doi: 10.1038/srep08394.", "ArticleIdList": ["10.1038/srep08394", "PMC4323656", "25670261"]}, {"Citation": "Murata H., Sakaguchi M., Jin Y., Sakaguchi Y., Futami J.-i., Yamada H., Kataoka K., Huh N.-h. A New Cytosolic Pathway from a Parkinson Disease-associated Kinase, BRPK/PINK1 ACTIVATION OF AKT VIA MTORC2. J. Biol. Chem. 2011;286:7182\u20137189. doi: 10.1074/jbc.M110.179390.", "ArticleIdList": ["10.1074/jbc.M110.179390", "PMC3044975", "21177249"]}, {"Citation": "Koehler M.F., Bergeron P., Blackwood E., Bowman K.K., Chen Y.-H., Deshmukh G., Ding X., Epler J., Lau K., Lee L. Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity. J. Med. Chem. 2012;55:10958\u201310971. doi: 10.1021/jm301389h.", "ArticleIdList": ["10.1021/jm301389h", "23199076"]}, {"Citation": "Gravina G.L., Marampon F., Sherris D., Vittorini F., Cesare E.D., Tombolini V., Lenzi A., Jannini E.A., Festuccia C. Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models. Prostate. 2014;74:852\u2013868. doi: 10.1002/pros.22804.", "ArticleIdList": ["10.1002/pros.22804", "24715588"]}, {"Citation": "Kladney R.D., Cardiff R.D., Kwiatkowski D.J., Chiang G.G., Weber J.D., Arbeit J.M., Lu Z.H. Tuberous sclerosis complex 1: An epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice. Cancer Res. 2010;70:8937\u20138947. doi: 10.1158/0008-5472.CAN-10-1646.", "ArticleIdList": ["10.1158/0008-5472.CAN-10-1646", "PMC3064856", "20940396"]}, {"Citation": "Nardella C., Chen Z., Salmena L., Carracedo A., Alimonti A., Egia A., Carver B., Gerald W., Cordon-Cardo C., Pandolfi P.P. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev. 2008;22:2172\u20132177. doi: 10.1101/gad.1699608.", "ArticleIdList": ["10.1101/gad.1699608", "PMC2518820", "18708577"]}, {"Citation": "Du Y., Long Q., Shi Y., Liu X., Li X., Zeng J., Gong Y., Li L., Wang X., He D. Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer. Oncol. Rep. 2015;34:2273\u20132281. doi: 10.3892/or.2015.4201.", "ArticleIdList": ["10.3892/or.2015.4201", "PMC4583521", "26323436"]}, {"Citation": "Zhou Y., Yang J., Zhang R., Kope\u010dek J.i. Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel. Eur. J. Pharm. Biopharm. 2015;89:107\u2013115. doi: 10.1016/j.ejpb.2014.11.025.", "ArticleIdList": ["10.1016/j.ejpb.2014.11.025", "PMC4355312", "25481033"]}, {"Citation": "Yu Z.-C., Cen Y.-X., Wu B.-H., Wei C., Xiong F., Li D.-F., Liu T.-T., Luo M.-H., Guo L.-L., Li Y.-X. Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats. World J. Gastroenterol. 2019;25:3956. doi: 10.3748/wjg.v25.i29.3956.", "ArticleIdList": ["10.3748/wjg.v25.i29.3956", "PMC6689801", "31413530"]}, {"Citation": "Jacinto E., Loewith R., Schmidt A., Lin S., R\u00fcegg M.A., Hall A., Hall M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 2004;6:1122. doi: 10.1038/ncb1183.", "ArticleIdList": ["10.1038/ncb1183", "15467718"]}, {"Citation": "Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.-H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell. 2006;22:159\u2013168. doi: 10.1016/j.molcel.2006.03.029.", "ArticleIdList": ["10.1016/j.molcel.2006.03.029", "16603397"]}, {"Citation": "Amato R.J., Wilding G., Bubley G., Loewy J., Haluska F., Gross M.E. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin. Genitourin. Cancer. 2012;10:232\u2013238. doi: 10.1016/j.clgc.2012.05.001.", "ArticleIdList": ["10.1016/j.clgc.2012.05.001", "PMC3963491", "22695254"]}, {"Citation": "Meulenbeld H.J., de Bono J.S., Tagawa S.T., Whang Y.E., Li X., Heath K.H., Zandvliet A.S., Ebbinghaus S.W., Hudes G.R., de Wit R. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC) Cancer Chemother. Pharmacol. 2013;72:909\u2013916. doi: 10.1007/s00280-013-2250-6.", "ArticleIdList": ["10.1007/s00280-013-2250-6", "23921574"]}, {"Citation": "Lu W., Li Y. Salinomycin suppresses LRP6 expression and inhibits both Wnt/\u03b2-catenin and mTORC1 signaling in breast and prostate cancer cells. J. Cell. Biochem. 2014;115:1799\u20131807. doi: 10.1002/jcb.24850.", "ArticleIdList": ["10.1002/jcb.24850", "PMC4134741", "24905570"]}, {"Citation": "Cheever M.A., Higano C.S. PROVENGE (Sipuleucel-T) in prostate cancer: The first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 2011;17:3520\u20133526. doi: 10.1158/1078-0432.CCR-10-3126.", "ArticleIdList": ["10.1158/1078-0432.CCR-10-3126", "21471425"]}, {"Citation": "Handy C.E., Antonarakis E.S. Sipuleucel-T for the treatment of prostate cancer: Novel insights and future directions. Future Oncol. 2018;14:907\u2013917. doi: 10.2217/fon-2017-0531.", "ArticleIdList": ["10.2217/fon-2017-0531", "PMC5925432", "29260582"]}, {"Citation": "Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010;363:411\u2013422. doi: 10.1056/NEJMoa1001294.", "ArticleIdList": ["10.1056/NEJMoa1001294", "20818862"]}, {"Citation": "Fung A.S., Wu L., Tannock I.F. Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin. Cancer Res. 2009;15:5389\u20135395. doi: 10.1158/1078-0432.CCR-08-3007.", "ArticleIdList": ["10.1158/1078-0432.CCR-08-3007", "19706800"]}, {"Citation": "Gr\u00fcnwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 2002;62:6141\u20136145.", "ArticleIdList": ["12414639"]}, {"Citation": "Carver B.S., Chapinski C., Wongvipat J., Hieronymus H., Chen Y., Chandarlapaty S., Arora V.K., Le C., Koutcher J., Scher H. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575\u2013586. doi: 10.1016/j.ccr.2011.04.008.", "ArticleIdList": ["10.1016/j.ccr.2011.04.008", "PMC3142785", "21575859"]}, {"Citation": "Siegel R., Naishadham D., Jemal A. Cancer statistics for hispanics/latinos, 2012. CA A Cancer J. Clin. 2012;62:283\u2013298. doi: 10.3322/caac.21153.", "ArticleIdList": ["10.3322/caac.21153", "22987332"]}, {"Citation": "Armstrong A.J., Shen T., Halabi S., Kemeny G., Bitting R.L., Kartcheske P., Embree E., Morris K., Winters C., Jaffe T. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clin. Genitourin. Cancer. 2013;11:397\u2013406. doi: 10.1016/j.clgc.2013.05.007.", "ArticleIdList": ["10.1016/j.clgc.2013.05.007", "23830964"]}, {"Citation": "Kruczek K., Ratterman M., Tolzien K., Sulo S., Lestingi T., Nabhan C. A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-na\u00efve castration-resistant prostate cancer. Br. J. Cancer. 2013;109:1711\u20131716. doi: 10.1038/bjc.2013.530.", "ArticleIdList": ["10.1038/bjc.2013.530", "PMC3790181", "24008662"]}, {"Citation": "Barata P.C., Cooney M., Mendiratta P., Gupta R., Dreicer R., Garcia J.A. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. Investig. New Drugs. 2019;37:331\u2013337. doi: 10.1007/s10637-018-0687-5.", "ArticleIdList": ["10.1007/s10637-018-0687-5", "30402678"]}, {"Citation": "Nakabayashi M., Werner L., Courtney K.D., Buckle G., Oh W.K., Bubley G.J., Hayes J.H., Weckstein D., Elfiky A., Sims D.M. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012;110:1729\u20131735. doi: 10.1111/j.1464-410X.2012.11456.x.", "ArticleIdList": ["10.1111/j.1464-410X.2012.11456.x", "22928480"]}, {"Citation": "Zhou S., Wang F., Wong E.T., Fonkem E., Hsieh T.-C., Wu J.M., Wu E. Salinomycin: A novel anti-cancer agent with known anti-coccidial activities. Curr. Med. Chem. 2013;20:4095\u20134101. doi: 10.2174/15672050113109990199.", "ArticleIdList": ["10.2174/15672050113109990199", "PMC4102832", "23931281"]}, {"Citation": "Rathkopf D.E., Larson S.M., Anand A., Morris M.J., Slovin S.F., Shaffer D.R., Heller G., Carver B., Rosen N., Scher H.I. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer. 2015;121:3853\u20133861. doi: 10.1002/cncr.29578.", "ArticleIdList": ["10.1002/cncr.29578", "PMC4618268", "26178426"]}, {"Citation": "Zhang W., Zhu J., Efferson C.L., Ware C., Tammam J., Angagaw M., Laskey J., Bettano K.A., Kasibhatla S., Reilly J.F. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res. 2009;69:7466\u20137472. doi: 10.1158/0008-5472.CAN-08-4385.", "ArticleIdList": ["10.1158/0008-5472.CAN-08-4385", "19738074"]}, {"Citation": "Templeton A.J., Dutoit V., Cathomas R., Rothermundt C., B\u00e4rtschi D., Dr\u00f6ge C., Gautschi O., Borner M., Fechter E., Stenner F. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08) Eur. Urol. 2013;64:150\u2013158. doi: 10.1016/j.eururo.2013.03.040.", "ArticleIdList": ["10.1016/j.eururo.2013.03.040", "23582881"]}, {"Citation": "Vaishampayan U., Shevrin D., Stein M., Heilbrun L., Land S., Stark K., Li J., Dickow B., Heath E., Smith D. Phase II trial of carboplatin, everolimus, and prednisone in metastatic castration-resistant prostate cancer pretreated with docetaxel chemotherapy: A prostate cancer clinical trial consortium study. Urology. 2015;86:1206\u20131211. doi: 10.1016/j.urology.2015.08.008.", "ArticleIdList": ["10.1016/j.urology.2015.08.008", "PMC6902637", "26375845"]}, {"Citation": "Graham L., Banda K., Torres A., Carver B.S., Chen Y., Pisano K., Shelkey G., Curley T., Scher H.I., Lotan T.L. A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Investig. New Drugs. 2018;36:458\u2013467. doi: 10.1007/s10637-018-0578-9.", "ArticleIdList": ["10.1007/s10637-018-0578-9", "PMC6050986", "29508246"]}, {"Citation": "Wei X.X., Hsieh A.C., Kim W., Friedlander T., Lin A.M., Louttit M., Ryan C.J. A phase I study of abiraterone acetate combined with BEZ235, a dual PI3K/mTOR inhibitor, in metastatic castration resistant prostate cancer. Oncologist. 2017;22:503. doi: 10.1634/theoncologist.2016-0432.", "ArticleIdList": ["10.1634/theoncologist.2016-0432", "PMC5423513", "28314838"]}, {"Citation": "Narayan V., Vapiwala N., Mick R., Subramanian P., Christodouleas J.P., Bekelman J.E., Deville C., Rajendran R., Haas N.B. Phase 1 trial of everolimus and radiation therapy for salvage treatment of biochemical recurrence in prostate cancer patients following prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 2017;97:355\u2013361. doi: 10.1016/j.ijrobp.2016.10.013.", "ArticleIdList": ["10.1016/j.ijrobp.2016.10.013", "27986349"]}, {"Citation": "Chow H., Ghosh P.M., deVere White R., Evans C.P., Dall\u2019Era M.A., Yap S.A., Li Y., Beckett L.A., Lara P.N., Jr., Pan C.X. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016;122:1897\u20131904. doi: 10.1002/cncr.29927.", "ArticleIdList": ["10.1002/cncr.29927", "PMC4892938", "27019001"]}, {"Citation": "De Bono J.S., De Giorgi U., Rodrigues D.N., Massard C., Bracarda S., Font A., Arija J.A.A., Shih K.C., Radavoi G.D., Xu N. Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. Clin. Cancer Res. 2019;25:928\u2013936. doi: 10.1158/1078-0432.CCR-18-0981.", "ArticleIdList": ["10.1158/1078-0432.CCR-18-0981", "30037818"]}, {"Citation": "Massard C., Chi K.N., Castellano D., de Bono J., Gravis G., Dirix L., Machiels J.-P., Mita A., Mellado B.a., Turri S. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. Eur. J. Cancer. 2017;76:36\u201344. doi: 10.1016/j.ejca.2017.01.024.", "ArticleIdList": ["10.1016/j.ejca.2017.01.024", "28282611"]}, {"Citation": "Fantini M., Benvenuto M., Masuelli L., Frajese G.V., Tresoldi I., Modesti A., Bei R. In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: Perspectives on cancer treatment. Int. J. Mol. Sci. 2015;16:9236\u20139282. doi: 10.3390/ijms16059236.", "ArticleIdList": ["10.3390/ijms16059236", "PMC4463587", "25918934"]}, {"Citation": "Erdogan S., Doganlar O., Doganlar Z.B., Serttas R., Turkekul K., Dibirdik I., Bilir A. The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K/Akt/NF-\u03baB signaling. Life Sci. 2016;162:77\u201386. doi: 10.1016/j.lfs.2016.08.019.", "ArticleIdList": ["10.1016/j.lfs.2016.08.019", "27569589"]}, {"Citation": "Kumar D., Shankar S., Srivastava R.K. Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway. Cancer Lett. 2014;343:179\u2013189. doi: 10.1016/j.canlet.2013.10.003.", "ArticleIdList": ["10.1016/j.canlet.2013.10.003", "24125861"]}, {"Citation": "Sinha I., Allen J.E., Pinto J.T., Sinha R. Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia. Cancer Med. 2014;3:252\u2013264. doi: 10.1002/cam4.198.", "ArticleIdList": ["10.1002/cam4.198", "PMC3987075", "24515947"]}, {"Citation": "Chen Y., Zheng L., Liu J., Zhou Z., Cao X., Lv X., Chen F. Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways. Int. Immunopharmacol. 2014;21:447\u2013455. doi: 10.1016/j.intimp.2014.05.026.", "ArticleIdList": ["10.1016/j.intimp.2014.05.026", "24905636"]}, {"Citation": "Wu X., He Y., Zhang G., Wu J., Hou Y., Gu Y., Chen H. Royleanone diterpenoid exhibits potent anticancer effects in LNCaP human prostate carcinoma cells by inducing mitochondrial mediated apoptosis, cell cycle arrest, suppression of cell migration and downregulation of mTOR/PI3K/AKT signalling pathway. J. Balk. Union Oncol. 2018;23:1055\u20131060.", "ArticleIdList": ["30358211"]}, {"Citation": "Meng Y., Lin Z.-M., Ge N., Zhang D.-L., Huang J., Kong F. Ursolic acid induces apoptosis of prostate cancer cells via the PI3K/Akt/mTOR pathway. Am. J. Chin. Med. 2015;43:1471\u20131486. doi: 10.1142/S0192415X15500834.", "ArticleIdList": ["10.1142/S0192415X15500834", "26503559"]}, {"Citation": "Shin S., Jing K., Jeong S., Kim N., Song K.-S., Heo J.-Y., Park J.-H., Seo K.-S., Han J., Park J.-I. The omega-3 polyunsaturated fatty acid DHA induces simultaneous apoptosis and autophagy via mitochondrial ROS-mediated Akt-mTOR signaling in prostate cancer cells expressing mutant p53. BioMed Res. Int. 2013;2013 doi: 10.1155/2013/568671.", "ArticleIdList": ["10.1155/2013/568671", "PMC3691929", "23841076"]}, {"Citation": "Selvaraj S., Sun Y., Sukumaran P., Singh B.B. Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathway. Mol. Carcinog. 2016;55:818\u2013831. doi: 10.1002/mc.22324.", "ArticleIdList": ["10.1002/mc.22324", "PMC4624064", "25917875"]}, {"Citation": "Guo Z., Hu X., Xing Z., Xing R., Lv R., Cheng X., Su J., Zhou Z., Xu Z., Nilsson S. Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway. Mol. Cell. Biochem. 2015;406:111\u2013119. doi: 10.1007/s11010-015-2429-8.", "ArticleIdList": ["10.1007/s11010-015-2429-8", "PMC4502300", "25957503"]}, {"Citation": "Aryal P., Kim K., Park P.H., Ham S., Cho J., Song K. Baicalein induces autophagic cell death through AMPK/ULK1 activation and downregulation of m TORC 1 complex components in human cancer cells. FEBS J. 2014;281:4644\u20134658. doi: 10.1111/febs.12969.", "ArticleIdList": ["10.1111/febs.12969", "25132405"]}, {"Citation": "Pratheeshkumar P., Budhraja A., Son Y.-O., Wang X., Zhang Z., Ding S., Wang L., Hitron A., Lee J.-C., Xu M. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS ONE. 2012;7:e47516. doi: 10.1371/journal.pone.0047516.", "ArticleIdList": ["10.1371/journal.pone.0047516", "PMC3475699", "23094058"]}, {"Citation": "Rashid A., Liu C., Sanli T., Tsiani E., Singh G., Bristow R.G., Dayes I., Lukka H., Wright J., Tsakiridis T. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiat. Oncol. 2011;6:144. doi: 10.1186/1748-717X-6-144.", "ArticleIdList": ["10.1186/1748-717X-6-144", "PMC3217881", "22029423"]}, {"Citation": "Friedrichs W., Ruparel S.B., Marciniak R.A., DeGraffenried L. Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression. Nutr. Cancer. 2011;63:771\u2013777. doi: 10.1080/01635581.2011.570892.", "ArticleIdList": ["10.1080/01635581.2011.570892", "21667400"]}, {"Citation": "Liu K., Park C., Li S., Lee K.W., Liu H., He L., Soung N.K., Ahn J.S., Bode A.M., Dong Z. Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2. Carcinogenesis. 2012;33:1406\u20131411. doi: 10.1093/carcin/bgs156.", "ArticleIdList": ["10.1093/carcin/bgs156", "PMC3405653", "22532249"]}, {"Citation": "Li G., Rivas P., Bedolla R., Thapa D., Reddick R.L., Ghosh R., Kumar A.P. Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: Involvement of SIRT1/S6K axis. Cancer Prev. Res. 2013;6:27\u201339. doi: 10.1158/1940-6207.CAPR-12-0349.", "ArticleIdList": ["10.1158/1940-6207.CAPR-12-0349", "PMC3536933", "23248098"]}, {"Citation": "Makhov P., Golovine K., Teper E., Kutikov A., Mehrazin R., Corcoran A., Tulin A., Uzzo R., Kolenko V. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. Br. J. Cancer. 2014;110:899\u2013907. doi: 10.1038/bjc.2013.810.", "ArticleIdList": ["10.1038/bjc.2013.810", "PMC3929888", "24434432"]}, {"Citation": "Predes F.S., Ruiz A.L., Carvalho J.o.E., Foglio M.A., Dolder H. Antioxidative and in vitro antiproliferative activity of Arctium lappa root extracts. BMC Complementary Altern. Med. 2011;11:25. doi: 10.1186/1472-6882-11-25.", "ArticleIdList": ["10.1186/1472-6882-11-25", "PMC3073957", "21429215"]}, {"Citation": "Lee Y.-J., Oh J.-E., Lee S.-H. Arctigenin shows preferential cytotoxicity to acidity-tolerant prostate carcinoma PC-3 cells through ROS-mediated mitochondrial damage and the inhibition of PI3K/Akt/mTOR pathway. Biochem. Biophys. Res. Commun. 2018;505:1244\u20131250. doi: 10.1016/j.bbrc.2018.10.045.", "ArticleIdList": ["10.1016/j.bbrc.2018.10.045", "30333093"]}, {"Citation": "Epstein M.M., Kasperzyk J.L., Mucci L.A., Giovannucci E., Price A., Wolk A., H\u00e5kansson N., Fall K., Andersson S.-O., Andr\u00e9n O. Dietary fatty acid intake and prostate cancer survival in \u00d6rebro County, Sweden. Am. J. Epidemiol. 2012;176:240\u2013252. doi: 10.1093/aje/kwr520.", "ArticleIdList": ["10.1093/aje/kwr520", "PMC3491963", "22781428"]}, {"Citation": "Yang Y.-C., Lee S.-G., Lee H.-K., Kim M.-K., Lee S.-H., Lee H.-S. A piperidine amide extracted from Piper longum L. fruit shows activity against Aedes aegypti mosquito larvae. J. Agric. Food Chem. 2002;50:3765\u20133767. doi: 10.1021/jf011708f.", "ArticleIdList": ["10.1021/jf011708f", "12059157"]}, {"Citation": "Pervaiz S. Resveratrol: From grapevines to mammalian biology. FASEB J. 2003;17:1975\u20131985. doi: 10.1096/fj.03-0168rev.", "ArticleIdList": ["10.1096/fj.03-0168rev", "14597667"]}, {"Citation": "Ko J.-H., Sethi G., Um J.-Y., Shanmugam M.K., Arfuso F., Kumar A.P., Bishayee A., Ahn K.S. The role of resveratrol in cancer therapy. Int. J. Mol. Sci. 2017;18:2589. doi: 10.3390/ijms18122589.", "ArticleIdList": ["10.3390/ijms18122589", "PMC5751192", "29194365"]}, {"Citation": "Bishayee A. Cancer prevention and treatment with resveratrol: From rodent studies to clinical trials. Cancer Prev. Res. 2009;2:409\u2013418. doi: 10.1158/1940-6207.CAPR-08-0160.", "ArticleIdList": ["10.1158/1940-6207.CAPR-08-0160", "19401532"]}, {"Citation": "Chen K.-H., Weng M.-S., Lin J.-K. Tangeretin suppresses IL-1\u03b2-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells. Biochem. Pharmacol. 2007;73:215\u2013227. doi: 10.1016/j.bcp.2006.09.018.", "ArticleIdList": ["10.1016/j.bcp.2006.09.018", "17067555"]}, {"Citation": "Zhu W.B., Xiao N., Liu X.J. Dietary flavonoid tangeretin induces reprogramming of epithelial to mesenchymal transition in prostate cancer cells by targeting the PI3K/Akt/mTOR signaling pathway. Oncol. Lett. 2018;15:433\u2013440. doi: 10.3892/ol.2017.7307.", "ArticleIdList": ["10.3892/ol.2017.7307", "PMC5766056", "29375715"]}, {"Citation": "Zoncu R., Efeyan A., Sabatini D.M. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011;12:21\u201335. doi: 10.1038/nrm3025.", "ArticleIdList": ["10.1038/nrm3025", "PMC3390257", "21157483"]}, {"Citation": "Bhattacharyya P., Bishayee A. Ocimum sanctum Linn.(Tulsi): An ethnomedicinal plant for the prevention and treatment of cancer. Anticancer. Drugs. 2013;24:659\u2013666. doi: 10.1097/CAD.0b013e328361aca1.", "ArticleIdList": ["10.1097/CAD.0b013e328361aca1", "23629478"]}, {"Citation": "Fang J., Zhou Q., Shi X.-l., Jiang B.-h. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis. 2007;28:713\u2013723. doi: 10.1093/carcin/bgl189.", "ArticleIdList": ["10.1093/carcin/bgl189", "17065200"]}, {"Citation": "Nagaprashantha L.D., Vatsyayan R., Singhal J., Fast S., Roby R., Awasthi S., Singhal S.S. Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem. Pharmacol. 2011;82:1100\u20131109. doi: 10.1016/j.bcp.2011.07.078.", "ArticleIdList": ["10.1016/j.bcp.2011.07.078", "PMC3252753", "21803027"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "6", "Day": "28"}, {"Year": "2021", "Month": "7", "Day": "29"}, {"Year": "2021", "Month": "7", "Day": "29"}, {"Year": "2021", "Month": "8", "Day": "28", "Hour": "1", "Minute": "5"}, {"Year": "2021", "Month": "8", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "8", "Day": "29", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "8", "Day": "3"}], "PublicationStatus": "epublish", "ArticleIdList": ["34452154", "PMC8400324", "10.3390/pharmaceutics13081195", "pharmaceutics13081195"]}}], "PubmedBookArticle": []}